



UNIVERSITY
OF WOLLONGONG
AUSTRALIA

University of Wollongong
Research Online

Illawarra Health and Medical Research Institute

Faculty of Science, Medicine and Health

2018

Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1

Sonia Sanz Munoz

University of Wollongong, ssm886@uowmail.edu.au

Rachelle Balez

University of Wollongong, rb478@uowmail.edu.au

Mauricio E Castro Cabral Da Silva

University of Wollongong, mcastro@uow.edu.au

Tracey Berg

University of Wollongong, tberg@uow.edu.au

Martin Engel

University of Wollongong, mengel@uow.edu.au

Publication Details

Sanz Munoz, S., Balez, R., E Castro Cabral Da Silva, M., Berg, T., Engel, M., Bax, M., Do-Ha, P., Stevens, C. H., Greenough, M., BUSH, A. & Ooi, L. (2018). Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1. *Stem Cell Research*, 31 227-230.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

See next page for additional authors

Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1

Abstract

The induced pluripotent stem cell (iPSC) lines UOWi002-A and UOWi003-A were reprogrammed from dermal fibroblasts via mRNA transfection. Dermal fibroblasts from a 56 year old female caucasian familial Alzheimer's disease patient carrying A246E mutation in the PSEN1 gene (familial AD3, autopsy confirmed Alzheimer's disease) and a 75 year old female non-demented control from the same family bearing the wild-type PSEN1 A246 genotype were obtained from the Coriell Institute (AG06848 and AG06846, respectively). The generated iPSCs were characterized and pluripotency was confirmed. The PSEN1 genotype was maintained in both iPSC lines.

Publication Details

Sanz Munoz, S., Balez, R., E Castro Cabral Da Silva, M., Berg, T., Engel, M., Bax, M., Do-Ha, P., Stevens, C. H., Greenough, M., BUSH, A. & Ooi, L. (2018). Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1. *Stem Cell Research*, 31 227-230.

Authors

Sonia Sanz Munoz, Rachelle Balez, Mauricio E Castro Cabral Da Silva, Tracey Berg, Martin Engel, Monique Bax, Phuong Dzung Do-Ha, Claire H. Stevens, Mark Greenough, Ashley I. BUSH, and Lezanne Ooi



Lab resource: Multiple Cell Lines

Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1



Sonia Sanz Muñoz^a, Rachelle Balez^a, Mauricio e Castro Cabral-da-Silva^a, Tracey Berg^a, Martin Engel^a, Monique Bax^a, Dzung Do-Ha^a, Claire H. Stevens^a, Mark Greenough^b, Ashley Bush^b, Lezanne Ooi^{a,*}

^a Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, NSW 2522, Australia

^b Florey Institute of Neuroscience & Mental Health, Level 4, Kenneth Myer Building, The University of Melbourne, Royal Parade, Parkville, VIC 3010, Australia

ABSTRACT

The induced pluripotent stem cell (iPSC) lines UOWi002-A and UOWi003-A were reprogrammed from dermal fibroblasts via mRNA transfection. Dermal fibroblasts from a 56 year old female caucasian familial Alzheimer's disease patient carrying A246E mutation in the *PSEN1* gene (familial AD3, autopsy confirmed Alzheimer's disease) and a 75 year old female non-demented control from the same family bearing the wild-type *PSEN1* A246 genotype were obtained from the Coriell Institute (AG06848 and AG06846, respectively). The generated iPSCs were characterized and pluripotency was confirmed. The *PSEN1* genotype was maintained in both iPSC lines.

Resource table.

| | | | |
|--------------------------------------|--|---------------------------------|--|
| Unique stem cell lines identifier | UOWi002-A UOWi003-A | Gene modification | No |
| Alternative names of stem cell lines | iPSC 6846.2 (UOWi002-A) iPSC 6848.2 (UOWi003-A) | Type of modification | N/A |
| Institution | Illawarra Health and Medical Research Institute, University of Wollongong | Associated disease | Non-demented control (UOWi002-A) Familial Alzheimer's disease (UOWi003-A) |
| Contact information of distributor | Lezanne Ooi, lezanne@uow.edu.au | Gene/locus | N/A (UOWi002-A) <i>PSEN1</i> A246E (UOWi003-A) |
| Type of cell lines | iPSC | Method of modification | N/A |
| Origin | Human | Name of transgene or resistance | N/A |
| Cell source | Dermal fibroblast | Inducible/constitutive system | N/A |
| Clonal | Single clone | Date archived/stock date | 24/04/2018 |
| Method of reprogramming | Transgene free | Cell line repository/bank | N/A |
| Multiline rationale | Family members, one demented patient with a familial Alzheimer's disease mutation and one non-demented control | Ethical approval | HE13/299 University of Wollongong Human Research Ethics Committee |

* Corresponding author.

E-mail address: lezanne@uow.edu.au (L. Ooi).

<https://doi.org/10.1016/j.scr.2018.08.006>

Received 2 May 2018; Received in revised form 17 July 2018; Accepted 8 August 2018

Available online 13 August 2018

1873-5061/ © 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1
Summary of lines.

| iPSC line names | Abbreviation in figures | Gender | Age | Ethnicity | Genotype of locus | Disease |
|-----------------|-------------------------|--------|-----|---------------------|--------------------|------------------------------|
| UOWi002-A | UOWi002-A | Female | 75 | Caucasian, Canadian | <i>PSEN1</i> A246 | Non-demented control |
| UOWi003-A | UOWi003-A | Female | 56 | Caucasian, Canadian | <i>PSEN1</i> A246E | Familial Alzheimer's disease |

Resource utility

These iPSC lines can be used as a familial Alzheimer's disease cell line model and an escapee non-demented control from the same family.

Resource details

Dermal fibroblasts from a 56 year old female Alzheimer's disease patient and a 75 year old female escapee from the same family (Nee et al., 1983) were obtained from the Coriell Institute (AG06848 and AG06846, respectively, Table 1). The StemMACS mRNA Reprogramming kit (Miltenyi Biotec) was used to generate the iPSC lines (UOWi003-A and UOWi002-A), following the manufacturer's instructions. The iPSC colonies were isolated and expanded as individual clones. The A246E mutation in the *PSEN1* gene was confirmed present in the UOWi003-A cell line and absent in the UOWi002-A cell line (Fig. 1A), consistent with the parental fibroblast lines. The selected clone for each cell line showed a normal karyotype with no abnormality detected in 15 cells at 400 bands per haploid set for either of the iPSC lines (Fig. 1B), and showed normal iPSC morphology (Fig. 1C). The iPSC lines were authenticated against their respective fibroblast lines via short tandem repeat (STR) profiling. Characterization of the clones was carried out by immunostaining, showing expression of the pluripotent markers Oct4 and SSEA-4 (Fig. 1C) and quantitative RT-PCR (qRT-PCR) showed increased mRNA expression of the pluripotent genes *POU5F1* by > 4000 fold and *NANOG* by 100 fold (Fig. 1D) in the iPSCs in comparison to their parental fibroblasts. Pluripotency was confirmed via PluriTest (Müller et al., 2011), with the UOWi002-A and UOWi003-A lines obtaining a Pluripotency Score of 24.16 and 18.64, respectively and a Novelty Score of 1.46 and 1.47, respectively (Fig. 1E). Differentiation potential of UOWi002-A and UOWi003-A was confirmed by differentiation into endodermal, mesodermal or ectodermal lineages. cDNA from each lineage was pooled in a 1:1:1 ratio and analysed using TaqMan hPSC Scorecard. Results showed upregulation of specific genes of the endoderm, mesoderm and ectoderm layer, while pluripotent genes were downregulated (Fig. 1F). (See Table 2.)

Materials and methods

Reprogramming of dermal fibroblasts into iPSCs

Fibroblasts were plated on Matrigel-coated plates (Corning) and cultured in Stemgent Pluriton Reprogramming Medium before reprogramming was carried out with the StemMACS mRNA Reprogramming kit (Miltenyi Biotec, #130-104-460). After daily mRNA transfection for 11 days, the iPSC colonies that appeared in the cultures were manually transferred to another Matrigel-coated plate for isolation and expansion, and maintained in TeSR-E8 (Stemcell Technologies) at 37 °C and 5% CO₂. This study was approved by the University of Wollongong Human Research Ethics Committee (HE13/299).

Sequencing

DNA was extracted using the ISOLATE II Genomic DNA Kit (Bioline) and amplified by PCR using MyTaq HS DNA Polymerase (Bioline) with *PSEN1* primers (Table 3). Sequencing reactions were performed using ABI BigDye Terminator v3.1 Ready Reaction Mix, separated using

3500xL Genetic Analyzer (Applied Biosystems) and analysed using BioEdit (Fig. 1A).

Karyotyping

Karyotyping of the iPSCs was performed by Sullivan Nicolaides Pathology Pty Ltd. (Bowen Hills, Australia) (Fig. 1B).

Immunofluorescence staining

iPSC colonies were fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.05% Triton-X for 15 min. Blocking was performed by incubation with 5% goat serum for 1 h at 22 °C and primary antibodies (Table 3) were incubated overnight at 4 °C. Samples were incubated with secondary antibody (Table 3) for 1 h at 22 °C followed by RedDot2 (1:200, Biotium) or Hoescht 33,342 (1 µg/ml, Life Technologies) for 10 min. Images were captured on a confocal microscope (Leica DMI6000B) and acquired using LAS AF software (Leica Microsystems) (Fig. 1C).

Quantitative reverse transcription polymerase chain reaction

mRNA was extracted using TriReagent (MRC Gene), DNA was removed using Turbo DNase kit (ThermoFisher Scientific) and cDNA was generated using Tetro Reverse Transcriptase (Bioline) as per manufacturer's instructions. *POU5F1* and *NANOG* expression was assessed in triplicate using SensiFast SYBR (Bioline) on Corbett RotorGene3000 (ThermoFisher Scientific), using *GAPDH* and *HPRT1* housekeeper genes (Fig. 1D, Table 3). The efficiency of each sample was determined using LinRegPCR (Ruijter et al., 2009) and analysis was performed using the $\Delta\Delta C_t$ method.

PluriTest

mRNA was analysed using Illumina HT 12v4 gene expression microarray via PluriTest (Müller et al., 2011) (Fig. 1E).

TaqMan hPSC scorecard

Direct differentiation of iPSC colonies to the three germ layers was performed. Endoderm was induced with STEMdiff Definitive Endoderm Kit (Stemcell Technologies). Mesoderm was induced using Mesoderm base medium (DMEM/F12, 0.5% FBS, 1% GlutaMAX, 1% MEM Non-essential aminoacids, 55 µM 2-mercaptoethanol, 45 µM ascorbic acid) with 100 ng/ml Activin A (only on day 1), 10 ng/ml FGF-2, 100 ng/ml BMP4 and 100 ng/ml VEGF for 7 days. Ectoderm was induced using Neural induction medium (DMEM/F12, 0.4% B27, 1% N2, 1% GlutaMAX, 1% MEM Non-essential aminoacids) with 1 µM LDN193189 for 2 days as iPSC colonies, and 2 µM SB431542 and 3 µM CHIR99021 for 7 days as embryoid bodies. cDNA from each culture was mixed in a 1:1:1 ratio to analyse 1 µg by TaqMan hPSC Scorecard (ThermoFisher) as per the manufacturer's instructions.

STR analysis

STR analysis of 18 locations was performed at Garvan Molecular Genetics Institute (Darlinghurst, Australia).




Fig. 1. Characterization of iPSC lines UOWi002-A and UOWi003-A.

Table 2
Characterization and validation.

| Classification | Test | Result | Data |
|-------------------------------------|---|---|--|
| Morphology | Photography | Normal | Fig. 1C |
| Phenotype | Immunocytochemistry | Expression of pluripotency markers Oct4 and SSEA-4 | Fig. 1C |
| | RT-qPCR | Cells express <i>POU5F1</i> and <i>NANOG</i> | Fig. 1D |
| Genotype | Karyotype (G-banding) and resolution | 46XX, resolution: 400 bph | Fig. 1B |
| Identity | Microsatellite PCR (mPCR) OR STR analysis | N/A 18 sites tested, matched | N/A Submitted in archive with journal |
| Mutation analysis (IF APPLICABLE) | Sequencing | Yes – mutation present in UOWi003-A and absent in UOWi002-A | Fig. 1A |
| | Southern Blot or WGS | N/A | N/A |
| Microbiology and virology | Mycoplasma | Luminescence, negative | Supplementary file 2 |
| Differentiation potential | PluriTest | Pluripotency score: UOWi002-A = 24.16 UOWi003-A = 18.64 Novelty score: UOWi002-A = 1.46 UOWi003-A = 1.47 Passed | Fig. 1E |
| Donor screening (OPTIONAL) | TaqMan hPSC scorecard | N/A | Fig. 1F |
| Genotype additional info (OPTIONAL) | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A | N/A |
| | Blood group genotyping | N/A | N/A |
| | HLA tissue typing | N/A | N/A |

Table 3
Reagents details.

| Antibodies used for immunocytochemistry/flow-citometry | | | |
|--|---|--|---|
| | Antibody | Dilution | Company Cat # and RRID |
| Pluripotency markers | OCT4 | 1:500 | Stemcell Technologies Cat# 01550, RRID: AB_1118539 |
| | SSEA4 | 1:200 | Abcam Cat# ab16287, RRID: AB_778073 |
| Secondary antibodies | Alexa Fluor 488 Goat anti-mouse IgG (H + L) | 1:1000 | ThermoFisher Scientific Cat# A11001, RRID: AB_2534069 |
| Primers | | | |
| | Target | Forward/reverse primer (5'-3') | |
| Sequencing | <i>PSEN1</i> | Forward: GGGAGCCATCACATTATTC Reverse: CCTGTGACAAACAAATTATCAG | |
| Pluripotency genes (qPCR) | <i>NANOG</i> | Forward: CCAGAACCAGAGAATGAAATC Reverse: TGGTGGTAGGAAGAGTAAAG | |
| | <i>POU5F1</i> | Forward: GATCACCTGGGATATACAC Reverse: GCTTGCATATCTCCTGAAG | |
| House-keeping genes (qPCR) | <i>GAPDH</i> | Forward: GAGCACAAGAGGAAGAGAGAGACCC Reverse: GTTGAGCACAGGGTACTTTATTGATGGTACATG | |
| | <i>HPRT1</i> | Forward: TGACACTGGCAAAACAATGCA Reverse: GGTCCTTTTACCAGCAAGCT | |

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2018.08.006>.

References

Müller, F.-J., Schuldt, B.M., Williams, R., Mason, D., Altun, G., Papapetrou, E., Danner, S.,

Goldman, J.E., Herbst, A., Schmidt, N.O., Aldenhoff, J.B., Laurent, L.C., Loring, J.F., 2011. A bioinformatic assay for pluripotency in human cells. *Nat. Methods* 8, 315–317. <https://doi.org/10.1038/nmeth.1580>.
Nee, L.E., Polinsky, R.J., Eldridge, R., Weingartner, H., Smallberg, S., Ebert, M., 1983. A family with histologically confirmed Alzheimer's disease. *Arch. Neurol.* 40, 203–208. <https://doi.org/10.1001/archneur.1983.04050040033004>.
Ruijter, J.M., Ramakers, C., Hoogaars, W.M.H., Karlen, Y., Bakker, O., van den Hoff, M.J.B., Moorman, A.F.M., 2009. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res.* 37, e45. <https://doi.org/10.1093/nar/gkp045>.